StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) stock

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3086% above fair value
$286.01−6.81 (-2.33%)

Close on Nov 18, 2026Market cap $505.41BP/E 80.8Yield 2.33%

AbbVie free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

AbbVie's free cash flow for the twelve months ending Jun 30, 2026 was $18.21B, down 0.2% year over year. For fiscal 2025 it was $17.82B, down 0.1% from the year before. Over ten years it grew 9.8% a year on average. The highest annual figure on record is $24.25B in fiscal 2022.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$17.82B-0.1%
FY2024Dec 31, 2024$17.83B-19.2%
FY2023Dec 31, 2023$22.06B-9.0%
FY2022Dec 31, 2022$24.25B+10.3%
FY2021Dec 31, 2021$21.99B+31.0%
FY2020Dec 31, 2020$16.79B+31.5%
FY2019Dec 31, 2019$12.77B-0.1%
FY2018Dec 31, 2018$12.79B+35.6%
FY2017Dec 31, 2017$9.43B+43.7%
FY2016Dec 31, 2016$6.56B-6.3%
FY2015Dec 31, 2015$7.00B+138.4%
FY2014Dec 31, 2014$2.94B-49.2%
FY2013Dec 31, 2013$5.78B-3.9%
FY2012Dec 31, 2012$6.01B+2.1%
FY2011Dec 31, 2011$5.89B–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.11B-36.2%
Q1 FY2026Mar 31, 2026$3.56B+154.6%
Q4 FY2025Dec 31, 2025$4.89B-27.6%
Q3 FY2025Sep 30, 2025$6.64B+27.8%
Q2 FY2025Jun 30, 2025$4.88B+140.6%
Q1 FY2025Mar 31, 2025$1.40B-63.6%
Q4 FY2024Dec 31, 2024$6.76B+48.6%
Q3 FY2024Sep 30, 2024$5.20B-29.3%
Q2 FY2024Jun 30, 2024$2.03B-66.9%
Q1 FY2024Mar 31, 2024$3.85B-4.3%
Q4 FY2023Dec 31, 2023$4.55B-37.0%
Q3 FY2023Sep 30, 2023$7.36B-0.9%
Q2 FY2023Jun 30, 2023$6.14B+26.3%
Q1 FY2023Mar 31, 2023$4.02B-15.3%
Q4 FY2022Dec 31, 2022$7.22B+47.6%
Q3 FY2022Sep 30, 2022$7.43B-3.8%
Q2 FY2022Jun 30, 2022$4.86B+3.6%
Q1 FY2022Mar 31, 2022$4.75B+1.2%
Q4 FY2021Dec 31, 2021$4.89B+6.8%
Q3 FY2021Sep 30, 2021$7.72B+37.5%
Q2 FY2021Jun 30, 2021$4.70B+61.2%
Q1 FY2021Mar 31, 2021$4.69B+27.1%
Q4 FY2020Dec 31, 2020$4.58B+47.0%
Q3 FY2020Sep 30, 2020$5.61B+27.5%
Q2 FY2020Jun 30, 2020$2.91B+24.0%
Q1 FY2020Mar 31, 2020$3.69B+26.8%
Q4 FY2019Dec 31, 2019$3.11B-4.8%
Q3 FY2019Sep 30, 2019$4.40B+3.7%
Q2 FY2019Jun 30, 2019$2.35B-14.6%
Q1 FY2019Mar 31, 2019$2.91B+15.2%
Q4 FY2018Dec 31, 2018$3.27B+36.1%
Q3 FY2018Sep 30, 2018$4.24B+34.9%
Q2 FY2018Jun 30, 2018$2.75B+46.6%
Q1 FY2018Mar 31, 2018$2.53B+25.9%
Q4 FY2017Dec 31, 2017$2.40B+68.3%
Q3 FY2017Sep 30, 2017$3.15B+134.5%
Q2 FY2017Jun 30, 2017$1.88B–
Q1 FY2017Mar 31, 2017$2.01B–
Q4 FY2016Dec 31, 2016$1.43B–
Q3 FY2016Sep 30, 2016$1.34B–

More AbbVie figures

See a number that looks wrong?